The risk of infections in adult patients with systemic lupus erythematosus: systematic review and meta-analysis

Author:

Pego-Reigosa José María12,Nicholson Lindsay3,Pooley Nick3,Langham Sue4,Embleton Nina5,Marjenberg Zoe3,Barut Volkan6,Desta Barnabas7,Wang Xia8,Langham Julia9,Hammond Edward R10

Affiliation:

1. Rheumatology Department, University Hospital of Vigo, Vigo

2. IRIDIS (Investigation in Rheumatology and Immune-Mediated Diseases) Study Group, IISGS (Instituto de Investigación Sanitaria Galicia Sur), Vigo, Spain

3. Systematic Review Group, Maverex Limited, Manchester

4. Health Economics Group, Maverex Limited, Manchester

5. Statistical Group, Maverex Limited, Manchester

6. Global Medical Affairs, AstraZeneca, Cambridge, UK

7. Global Pricing and Market Access, AstraZeneca, Gaithersburg, MD

8. Data Science & AI, AstraZeneca, Gaithersburg, MD, USA

9. Epidemiology Group, Maverex Limited, Manchester, UK

10. BioPharmaceuticals Medical , AstraZeneca, Gaithersburg, MD, USA

Abstract

Abstract Objectives We conducted a systematic review and meta-analysis to determine the magnitude of infection risk in patients with SLE and evaluate the effect of general and SLE-related factors on infection risk. Methods We searched MEDLINE and Embase from inception to July 2018, screening for observational studies that evaluated infection risk in patients with SLE compared with the general population/healthy controls. Outcomes of interest included overall severe infection, herpes zoster infection/reactivation, opportunistic infections, pneumonia and tuberculosis. Random-effects models were used to calculate pooled risk ratios (RRs) for each type of infection. Sensitivity analysis assessed the impact of removing studies with high risk of bias. Results Eleven retrospective or prospective cohort studies were included in the meta-analysis: overall severe infection (n = 4), pneumonia (n = 6), tuberculosis (n = 3) and herpes zoster (n = 2). Pooled RRs for overall severe infection significantly increased for patients with SLE compared with the general population/healthy controls [RR 2.96 (95% CI 1.28, 6.83)]. Pooled RRs for pneumonia, herpes zoster and tuberculosis showed significantly increased risk compared with the general population/healthy controls [RR 2.58 (1.80, 3.70), 2.50 (2.36, 2.65) and 6.11 (3.61, 10.33), respectively]. Heterogeneity and evidence of publication bias were present for all analyses, except herpes zoster. Sensitivity analyses confirmed robustness of the results. Conclusion Patients with SLE have significantly higher risk of infection compared with the general population/healthy controls. Efforts to strengthen strategies aimed at preventing infections in SLE are needed. Protocol registration PROSPERO number: CRD42018109425.

Funder

AstraZeneca

Publisher

Oxford University Press (OUP)

Subject

Pharmacology (medical),Rheumatology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3